Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

Rebekah L. Browning; Susan M. Geyer; Amy J. Johnson; Diane F. Jelinek; Renee C. Tschumper; Timothy G. Call; Tait D. Shanafelt; Clive S. Zent; Nancy D. Bone; Gordon W. Dewald; Thomas S. Lin; Nyla A. Heerema; Michael R. Grever; Neil E. Kay; John C. Byrd; David M. Lucas

doi:10.1016/j.leukres.2007.05.020

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

Rebekah L. Browning
, Susan M. Geyer
, Amy J. Johnson
, Diane F. Jelinek
, Renee C. Tschumper
, Timothy G. Call
, Tait D. Shanafelt
, Clive S. Zent
, Nancy D. Bone
, Gordon W. Dewald
, Thomas S. Lin
, Nyla A. Heerema
, Michael R. Grever
, Neil E. Kay
, John C. Byrd
, David M. Lucas

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p = 0.046). Trends toward improved complete remission rate (49% versus 19%, p = 0.064) and progression-free survival (medians: 33 versus 20 months, p = 0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.

Original language	English (US)
Pages (from-to)	1737-1740
Number of pages	4
Journal	Leukemia Research
Volume	31
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2007.05.020
State	Published - Dec 2007

Keywords

Chemoimmunotherapy
Chronic lymphocytic leukemia (CLL)
Pentostatin
Prognostic factor
TCL-1

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2007.05.020

Cite this

Browning, R. L., Geyer, S. M., Johnson, A. J., Jelinek, D. F., Tschumper, R. C., Call, T. G., Shanafelt, T. D., Zent, C. S., Bone, N. D., Dewald, G. W., Lin, T. S., Heerema, N. A., Grever, M. R., Kay, N. E., Byrd, J. C., & Lucas, D. M. (2007). Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research, 31(12), 1737-1740. https://doi.org/10.1016/j.leukres.2007.05.020

Browning, RL, Geyer, SM, Johnson, AJ, Jelinek, DF, Tschumper, RC, Call, TG, Shanafelt, TD, Zent, CS, Bone, ND, Dewald, GW, Lin, TS, Heerema, NA, Grever, MR, Kay, NE, Byrd, JC & Lucas, DM 2007, 'Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia', Leukemia Research, vol. 31, no. 12, pp. 1737-1740. https://doi.org/10.1016/j.leukres.2007.05.020

@article{7cb70f98d1084c778419026a9f04b0f5,

title = "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia",

abstract = "TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52\% versus 17\%, p = 0.046). Trends toward improved complete remission rate (49\% versus 19\%, p = 0.064) and progression-free survival (medians: 33 versus 20 months, p = 0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.",

keywords = "Chemoimmunotherapy, Chronic lymphocytic leukemia (CLL), Pentostatin, Prognostic factor, TCL-1",

author = "Browning, \{Rebekah L.\} and Geyer, \{Susan M.\} and Johnson, \{Amy J.\} and Jelinek, \{Diane F.\} and Tschumper, \{Renee C.\} and Call, \{Timothy G.\} and Shanafelt, \{Tait D.\} and Zent, \{Clive S.\} and Bone, \{Nancy D.\} and Dewald, \{Gordon W.\} and Lin, \{Thomas S.\} and Heerema, \{Nyla A.\} and Grever, \{Michael R.\} and Kay, \{Neil E.\} and Byrd, \{John C.\} and Lucas, \{David M.\}",

note = "Funding Information: This work supported by the National Cancer Institute (NEK), The Leukemia and Lymphoma Society of America (JCB), and The D. Warren Brown Foundation (JCB). ",

year = "2007",

month = dec,

doi = "10.1016/j.leukres.2007.05.020",

language = "English (US)",

volume = "31",

pages = "1737--1740",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

AU - Browning, Rebekah L.

AU - Geyer, Susan M.

AU - Johnson, Amy J.

AU - Jelinek, Diane F.

AU - Tschumper, Renee C.

AU - Call, Timothy G.

AU - Shanafelt, Tait D.

AU - Zent, Clive S.

AU - Bone, Nancy D.

AU - Dewald, Gordon W.

AU - Lin, Thomas S.

AU - Heerema, Nyla A.

AU - Grever, Michael R.

AU - Kay, Neil E.

AU - Byrd, John C.

AU - Lucas, David M.

N1 - Funding Information: This work supported by the National Cancer Institute (NEK), The Leukemia and Lymphoma Society of America (JCB), and The D. Warren Brown Foundation (JCB).

PY - 2007/12

Y1 - 2007/12

N2 - TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p = 0.046). Trends toward improved complete remission rate (49% versus 19%, p = 0.064) and progression-free survival (medians: 33 versus 20 months, p = 0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.

AB - TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p = 0.046). Trends toward improved complete remission rate (49% versus 19%, p = 0.064) and progression-free survival (medians: 33 versus 20 months, p = 0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.

KW - Chemoimmunotherapy

KW - Chronic lymphocytic leukemia (CLL)

KW - Pentostatin

KW - Prognostic factor

KW - TCL-1

UR - https://www.scopus.com/pages/publications/35748953775

UR - https://www.scopus.com/pages/publications/35748953775#tab=citedBy

U2 - 10.1016/j.leukres.2007.05.020

DO - 10.1016/j.leukres.2007.05.020

M3 - Article

C2 - 17659340

AN - SCOPUS:35748953775

SN - 0145-2126

VL - 31

SP - 1737

EP - 1740

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this